Does Rallies show 13F holders for CYTK?

Yes. Rallies tracks hedge fund and 13F ownership data for CYTK, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CYTK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CYTK. It does not provide personalized investment advice.

CYTK (Cytokinetics Inc.) Stock Analysis - Hedge Fund Holdings

Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of May 21, 2026, CYTK trades at $78.84 with a market cap of $10.21B and a P/E ratio of -11.44. CYTK moved +2.97% today. Year to date, CYTK is +28.58%; over the trailing twelve months it is +141.18%. Its 52-week range spans $29.31 to $80.20. Analyst consensus is strong buy with an average price target of $100.18. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CYTK stock?

Hedge funds tracked by Rallies that own CYTK include Orbimed Advisors, Pentwater Capital, Redmile Group, Panagora Asset, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cytokinetics Inc..

CYTK Key Metrics

Key financial metrics for CYTK
Metric	Value
Price	$78.84
Market Cap	$10.21B
P/E Ratio	-11.44
EPS	$-6.84
Dividend Yield	0.00%
52-Week High	$80.20
52-Week Low	$29.31
Volume	308
Avg Volume	0
Revenue (TTM)	$105.81M
Net Income	$-829.61M
Gross Margin	0.00%

Top Hedge Funds Holding CYTK

Orbimed Advisors holds 1.08M shares of CYTK, changed -28.64% as of Jun 30, 2025.
Pentwater Capital holds 300.00K shares of CYTK, changed +0.00% as of Sep 30, 2025.
Redmile Group holds 82.10K shares of CYTK, changed -11.34% as of Mar 31, 2025.
Panagora Asset holds 44.63K shares of CYTK, changed -5.74% as of Jun 30, 2025.
Pinebridge Investments holds 36.40K shares of CYTK, changed +42.68% as of Dec 31, 2024.

Latest CYTK News

Cytokinetics Opens Free Registration for May 29 CLIMB Symposium with Phase 3 Updates — May 14, 2026
Cytokinetics Hosts May 19 Fireside Chat at RBC Healthcare Conference with 90-Day Replay — May 12, 2026
Cytokinetics Shows Aficamten Outperforms Metoprolol and Sustains Safety through 96 Weeks — May 11, 2026
Cytokinetics Prices 9.86M Shares at $71, Raising $700M — May 7, 2026
Cytokinetics drops as $650 million common-stock offering sparks dilution fears — May 6, 2026

Recent CYTK Insider Trades

Blum Robert I sold 7.50K (~$584.40K) on May 14, 2026.
Malik Fady Ibraham sold 3.50K (~$270.80K) on May 5, 2026.
WIERENGA WENDELL sold 4.03K (~$302.40K) on May 5, 2026.

CYTK Analyst Consensus

19 analysts cover CYTK: 0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $100.18.

Common questions about CYTK

Who owns CYTK stock?: Hedge funds tracked by Rallies that own CYTK include Orbimed Advisors, Pentwater Capital, Redmile Group, Panagora Asset, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cytokinetics Inc..
Does Rallies show 13F holders for CYTK?: Yes. Rallies tracks hedge fund and 13F ownership data for CYTK, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CYTK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CYTK. It does not provide personalized investment advice.